Tag:
R&D
Latest Headlines
Latest Headlines
UPDATED: Takeda beefs up new vaccines arm with $250M bolt-on buyout of Inviragen
A couple of months after moving its experimental dengue vaccine into the second phase of a mid-stage study, Fort Collins, CO-based Inviragen has been snapped up by Takeda in a $250 million deal.
Langer's Kala touts positive results for topical wet AMD treatment
Kala Pharmaceuticals is developing a novel way to get drugs into the eye, and the company notched some positive results in preclinical studies, finding that its platform led to higher drug concentration for a retinal treatment.
UPDATED: Biotech trio to take over Alderley labs as AstraZeneca heads south
It's the start of what locals hope will be a continued migration of smaller companies to the Alderley campus to fill the void of AZ's massive exit from the area.
GlaxoSmithKline's 'independent experts' start to hand out keys to its data vault
Despite a major backlash in the industry, GSK has agreed to open up the data vault to investigators who intend to publish their findings, accelerating a move in the industry to provide greater transparency to the public. But the pharma giant's "independent experts" selected to run the program include at least two people with close ties to GSK.
NGM raises $13M for cardio/metabolic R&D work
The company, which includes Genentech legend Art Levinson on its board, has been engaged in basic scientific research for the past 5 years, with a special focus on cardio/metabolic work.
Johnson & Johnson, Pfizer target painkiller revivals as FDA warms to abuse deterrents
The FDA has fueled a pharmaceutical arms race in the painkiller market with the agency's decision last month to bar the sale and production of generic OxyContin, which has become one of the most widely abused opioids among Americans.
Fetus secretes hormone that could flag preeclampsia risk
The hormone adrenomedullin is secreted by the fetus during pregnancy and appears to keep pregnant women from developing preeclampsia. And they believe it could become an effective biomarker to help pinpoint patients more likely to develop the dangerous condition.
9 blood-based biomarkers correspond to amyloid plaque in the brain
Researchers in Australia have identified 9 blood-based biomarkers that correspond with PET imaging measurements of amyloid beta protein, a brain plaque that can signify the advance of Alzheimer's disease.
Charles River's income slides on flat sales
Charles River Labs saw its net profits decline about 2.3% last quarter, as risings costs negated 1.8% revenue growth.
Novartis probes controversy around Diovan studies
Novartis has opened an investigation after learning that a company employee was affiliated with a study of its blood pressure drug Diovan as a statistician without revealing his ties to the Swiss healthcare giant.
